Emil Larsson’s Post

Fascinating developments in Alzheimer's treatment: I'm attending AlzeCure's live expert event on Gamma-Secretase Modulators! Excited to be virtually attending AlzeCure Pharma's upcoming event on Advances in Alzheimer's Disease Treatment: Small Molecule Gamma-Secretase Modulators as Promising Disease-Modifying Therapies. This event features esteemed Professor Henrik Zetterberg discussing cutting-edge Alzheimer's science, with a focus on recent therapeutic and diagnostic advancements. Additionally, AlzeCure's CEO and CSO will delve into their promising Alzstatin platform and its potential to combat Alzheimer's. Gamma-Secretase Modulators (GSMs) represent a novel approach in Alzheimer's treatment, and I'm particularly interested in learning more about: AlzeCure's Alzstatin platform: How it selectively targets Aβ42 oligomers while preserving other signaling pathways, unlike earlier GSIs. Clinical data from Roche's RG6289: Validating the GSM approach and showcasing its safety and efficacy potential. AlzeCure's NeuroRestore program: Exploring its potential cognitive benefits and disease-modifying effects. Join me virtually on February 19th at 3:00 PM CET (9:00 AM EST): https://lnkd.in/egyi-2RJ Let's discuss the future of Alzheimer's treatment! #Alzheimers #GSMs #AlzeCure #NeuroScience #ResearchMatters Please note: I am not affiliated with AlzeCure Pharma, but I am genuinely interested in this event and the potential of GSMs in Alzheimer's treatment.

The importance of testing #blood for #biomarkers is brilliantly highlighted here in this article

Alongside the many breakthroughs in the #Alzheimers #DrugDevelopment space, the diagnostics landscape is rapidly evolving, too. Researchers are exploring ways to improve the accessibility and scalability of #amyloid blood tests, and working to validate the complementary #biomarkers that will support drug development. Our Co-Founder and Chief Science Officer, Howard Fillit, MD, connected with Rowan Walrath of C&EN to discuss the ADDF's Diagnostics Accelerator (DxA) and its funding of blood-based biomarkers and #digital diagnostic tools, offering his prediction that #BloodTests will eventually replace the current gold standard PET scans and spinal taps for Alzheimer's #diagnosis. Throughout the article, diagnostic and biomarker research by ADDF- and DxA-funded investigators and biotechs like C2N Diagnostics, ALZpath Inc., Quanterix, RetiSpec, Rhoda Au, and DiaMiR Bio are mentioned. Read the full article here: https://bit.ly/3JaGZXR

INOVIQ Ltd (ASX:IIQ) is pleased to announce that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer’s Disease. Initial analytical and clinical validation studies showed: ✔ Exosomes isolated from blood using NEURO-NET contain proteins known to be expressed by brain cells; ✔ NEURO-NET was superior to other commercially available methods tested in isolating brain-derived exosomes from blood; ✔ NEURO-NET enabled the identification of known Alzheimer’s biomarkers in exosomes that could not be detected by other methods; ✔ Analysis of NEURO-NET-captured exosomes identified more than 200 proteins that were differentially expressed in Alzheimer’s patients when compared with healthy individuals. To find out more go to: https://lnkd.in/gTep2tzk #INOVIQ #NEURONET #Alzheimers #Exosomes #Therapeutics #Diagnostics #Research

I enjoyed hearing Simon Beaulah present on the interesting work and mission of PrecisionLife at the CIC (Cambridge Innovation Center) Venture Café yesterday evening. It’s exciting to see progress in the identification of subpopulations of patients living with chronic diseases, and consider the impact this information could have on: - The identification of novel drug targets - The design of clinical trials - How diagnostic tools are linked with treatment approvals - How the industry may need to adapt as precision medicine makes once ‘common’ diseases rare via the subcategorisation of patient groups

The world is rapidly aging - and along with this growth rate, we will see an increase in the prevalence of neurodegenerative diseases like Alzheimer’s. This means that if Alzheimer’s disease hasn’t already touched your family or loved ones, it may do so in the future. And we know how tough a diagnosis this can be for not only patients but their loved ones. The good news is that the science is evolving and that this is an area where there is increasing investment and focus from an R&D perspective. I am proud to work for a company that is committed to the Neuroscience space and is researching and developing novel treatment options for Alzheimer’s disease and other dementias. #WorldAlzheimersDay #WorldAlzMonth #AlzheimersDisease #JNJNeuroscience

Hello My Linkedin Community!! Today my article is about the ALZHEIMER DISEASE RECENT DEVELOPMENTS As of my last knowledge update in January 2022, I don't have specific information on developments in Alzheimer's disease within the last year. However, research in this field is ongoing, and several promising avenues have been explored. One notable focus has been on identifying biomarkers for early detection. Researchers are investigating blood and imaging biomarkers that may indicate the presence of Alzheimer's disease before symptoms become apparent. Early detection is crucial for developing effective interventions. Additionally, there has been increased interest in precision medicine approaches. Tailoring treatments based on an individual's genetic and molecular profile could enhance effectiveness and minimize side effects. Clinical trials of potential Alzheimer's drugs continue, with some aiming to target specific biological pathways associated with the disease. These include efforts to reduce the accumulation of beta-amyloid plaques and tau tangles in the brain, which are characteristic features of Alzheimer's. Collaborative efforts between academia, pharmaceutical companies, and advocacy groups are fostering a comprehensive approach to understanding and treating Alzheimer's disease. Public awareness campaigns are also working to reduce stigma and promote early diagnosis. It's recommended to check recent scientific journals, medical news, or official health organizations for the latest developments beyond my last update in January 2022. #snsinstitutions #snsdesignthinkers #designthinking

The number of people with Alzheimer’s disease (AD) and other dementias is expected to reach 139 million in 2050. Statistics like this reinforce our unwavering commitment to developing precision approaches for the early detection and potential treatment of AD. Watch the video below to learn more about how our biomarker research is accelerating clinical development for preclinical and early AD. #WorldAlzheimersDay #WorldAlzMonth #AlzheimersDisease #JNJNeuroscience

On World Parkinson's Day, we're excited to share groundbreaking research being conducted using our human-based in-vitro model, the NeuroHTS™ platform.   🔬 Research Breakthrough: Using the NeuroHTS™ platform, we organize hiPSC neurons derived from healthy individuals and Parkinson's disease (PD) donors into standardized networks. Our proprietary software compares over 3,000 data points of the network's morphology from a single assay, enabling us to identify key differences and pathways affected in cells from Parkinson's disease.   💡 Rapid Drug Screening: We leverage this cutting-edge technology as a rapid and reliable drug screening tool to differentiate the effects of therapeutic candidates for Parkinson's Disease and identify those that can significantly improve the morphology of neuronal networks from a Parkinson’s patient in a dose-responsive manner. Our assays streamline the drug development pipeline, optimizing resource allocation and focusing on advancing treatments for Parkinson's Disease.   🌟 Our Mission: Our aim is to consistently deliver fast, reliable, scalable, and physiologically relevant results to help de-risk early-stage drug development in neurodegenerative diseases. We are committed to making a meaningful impact in the lives of individuals living with Parkinson's disease and their families by accelerating the development of innovative treatments.   Join us in celebrating the progress we've made and continue to make in the fight against Parkinson's disease. #WorldParkinsonsDay #ParkinsonsAwareness #NeuroHTS #Innovation #Research #DrugDevelopment #HopeForPD

🤝 Strategic Partnership Update: AriBio and Neurophet Collaborate for Alzheimer's Research AriBio is pleased to announce a key collaboration with 뉴로핏 (Neurophet), aimed at advancing Alzheimer's research. This partnership involves integrating Neurophet's brain image analysis technology—Neurophet SCALE PET and Neurophet AQUA—into our ongoing phase 3 clinical trial of AR1001, an investigational drug for early Alzheimer's disease. Neurophet's technology will play a crucial role in identifying suitable candidates for our clinical trials, enhancing the precision of our research. This collaboration marks the convergence of AriBio's clinical expertise with 뉴로핏 (Neurophet)'s AI-driven imaging capabilities, offering a targeted approach to treatment. Our shared goal is to advance Alzheimer's treatment by leveraging the strengths of both fields—AI and drug development. We believe this strategic collaboration will streamline our clinical trials and contribute significantly to the development of new therapeutic and diagnostic approaches. Follow our journey as we navigate this collaboration and work towards innovative solutions for the complexities of Alzheimer's disease. Stay tuned for updates! #AriBio #Neurophet #AlzheimersResearch #ClinicalTrials #AIinHealthcare #alzheimersdisease #alzheimers